Based on the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P‐TIMI 50) trial,23 a multivariable risk model was derived for cardiovascular death, MI, and ischemic stroke over a median 2.5 years in 8598 placebo‐treated patients recruited 2 weeks to 1‐year post‐MI. Here, F2R is linked to ischemic stroke.